|
1.Livraghi, T., et al., Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology, 2008. 47(1): p. 82-89. 2.Szyszko, T., et al., Therapy options for treatment of hepatic malignancy. European Journal of Nuclear Medicine and Molecular Imaging, 2008. 35(10): p. 1824-1826. 3.Bhattarai, N., et al., Chitosan-based hydrogels for controlled, localized drug delivery. Advanced Drug Delivery Reviews, 2010. 62(1): p. 83-99. 4.Berrada, A., et al., A novel non-toxic camptothecin formulation for cancer chemotherapy. Biomaterials, 2005. 26: p. 2115–2120. 5.Azhdarinia, A., et al., Regional Radiochemotherapy Using In Situ Hydrogel. Pharmaceutical Research, 2005. 22(5): p. 776-783. 6.Ruel-Gariépy, E., et al., Characterization of thermosensitive chitosan gels for the sustained delivery of drugs. International Journal of Pharmaceutics, 2000. 203(1-2): p. 89-98. 7.Molinaro, G., et al., Biocompatibility of thermosensitive chitosan-based hydrogels: an in vivo experimental approach to injectable biomaterials. Biomaterials, 2002. 23: p. 2717–2722. 8.Chenite, A., et al., A. Novel injectable neutral solutions of chitosan form biodegradible gels in situ for bioactive therapeutic delivery, Biomaterials, 2000. 21: p. 2155-2161. 9.Ono, K., et al., Photocrosslinkable chitosan as a biological adhesive, J. Biomed. Mater. Res., 2000. 49(part A): p. 289–295. 10.Ishihara, M., et al., Chitosan hydrogel as a drug delivery carrier to control angiogenesis, J.Artif. Organs., 2006. 9: p. 8–16. 11.Obara, K., et al., Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice, J. Control. Release, 2005. 110: p. 79–89. 12.Buschmann, M., et al., Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state, Canada Patent WO, 2007. 0513112007. 13.Ruel-Gariepy, E., et al., A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel, Eur. J. Pharm. Biopharm, 2004. 57: p. 53–63. 14.Chenite, A., et al., Rheological characterisation of thermogelling chitosan/glycerol-phosphate solutions, Carbohydr. Polym, 2001. 46: p. 39–47. 15.Cho, J., et al., Physical gelation of chitosan in the presence of b-glycerophosphate: the effect of temperature, Biomacromolecules, 2005. 6: p. 3267–3275. 16.Hang Thu Ta, et al., Injectable chitosan hydrogels for localized cancer therapy, Journal of Controlled Release, 2008. 126: p. 205-216. 17.Ruel-Gariepy, E., et al., Thermosensitive chitosan-based hydrogel containing liposomes for the delivery of hydrophilic molecules, J. Control. Release, 2002. 82: p. 373–383. 18.Han, H.D., et al., A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combiningwith a vaccinia viral vaccine, Int. J. Pharm, 2008. 350: p. 27–34. 19.Kwon, S., et al., Physicochemical characteristics of self-assembled nanoparticles based on glycol chitosan bearing 5β-cholanic acid, Langmuir, 2003. 19: p. 10188–10193. 20.Min, K.H., et al., Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy, Journal of Controlled Release, 2008. 127: p. 208-218 21.Van-Hattum, A.H., et al., The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer, Biochem. Pharmacol, 2002. 64: p. 1267–1277. 22.Lerchen, H.G., et al., Design and optimization of 10-O-linked camptothecin glycoconjugates as anticancer agents, J. Med. Chem, 2001. 44: p. 4186–4195. 23.Knoght, V., et al., Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice, Cancer Chemother. Pharmacol, 1999. 44: p. 177–186. 24.Herben, V.M., et al., Clinical pharmacokinetics of topotecan, Clin. Pharmacokinet, 1996. 31: p. 85–102. 25.Gottlieb, J.A., et al., Treatment of malignant melanoma with camptothecin (NSC-100880), Cancer Chemother. Rep, 1972. 56: p. 103–105. 26.Moertel, C.G., et al., Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer, Cancer Chemother. Rep., 1972. 56: p. 95–101. 27.Muggia, F.M., et al., Phase I clinical trial of weekly and daily treatment with camptothecin: correlation with pre-clinical studies, Cancer Chemother. Rep., 1972. 56: p. 515–521. 28.Weingart, J.D., et al., Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the intracranial 9 L aliosarcoma model, Int. J. Cancer, 1995. 62: p. 605–609. 29.Storm, P.B., et al., Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy, J. Neurooncol, 2002. 56: p. 209–217. 30.Jain, R.A., et al., The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials, 2000. 21: p. 2475–2490. 31.Fassberg, J., et al., A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues, J. Pharm, 1992. 81: p. 676–684. 32.Hertberg, R.P., et al., Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity, J.Med. Chem, 1989. 32:p. 715–720. 33.Burke, T.G., et al., The structural basis of camptothecin interactions with human serum albumin: impact on drug stability, J. Med. Chem, 1994. 37: p. 40–46. 34.Hwang, H.Y., et al., Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles, J. Control. Release., 2008. 128: p. 23-31 35.Qi, L., et al., In vitro and in vivo suppression of hepatocellular carcinoma growth by chitosan nanoparticles. European Journal of Cancer, 2007. 43(1): p. 184-193. 36.Hamoudeh, M., et al., Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer, Advanced Drug Delivery Reviews, 2008. 60: p. 1329–1346 37.Garrean, S. et al., Yttrium-90 internal radiation therapy for hepatic malignancy. Surgical Oncology, 2005. 14(4): p. 179-193. 38.Sundram, F., Radionuclide therapy of hepatocellular carcinoma. 2006. 39.Changa, Y.J., et al., Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model. Nuclear Medicine and Biology, 2010. 37: p. 95–104 40.Azab, A. K., et al., Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 131I-norcholesterol. J. Control. Release, 2007. 123: p. 116–122. 41.Zhi-kui, C., et al., US-guided interstitial chemotherapy using paclitaxel temperature-responsive gel for breast cancer treatment in rat. Journal of Cancer Research and Clinical Oncology, 2010. 136(4): p. 537-545. 42.Chen, Z. k., et al., Interstitial chemotherapy using thermosensitive gel-coated ricin in nude mice bearing a human hepatoma. Hepatology Research, 2010. 40: p. 188–195 43.Huang, L. K. et al., Local delivery of rhenium-188 colloid into hepatic tumor sites in rats using thermo-sensitive chitosan hydrogel: effects of gelling time of chitosan as delivery system. J Radioanal Nucl Chem, 2011. 290: p. 39–44 44.Kwak, M., et al., Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent. Investigational New Drugs, 2010. 28(3): p. 284-290. 45.Dang, Q.F., et al., Controlled gelation temperature, pore diameter and degradation of a highly porous chitosan-based hydrogel. Carbohydrate Polymers, 2011. 83: p.171-178 46.Soundararajan, A., et al., [186Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nuclear Medicine and Biology, 2009. 36(5): p. 515-524. 47.Kang, G.D., et al., Controlled release of doxorubicin from thermosensitive poly(organophosphazene) hydrogels. International Journal of Pharmaceutics, 2006. 319(1-2): p. 29-36. 48.Stabin, M.G. et al., Physical Models and Dose Factors for Use in Internal Dose Assessment. Health Physics, 2003. 85(3): p. 294-310. 49.Chang, C.-H., et al., Comparative Dosimetric Evaluation of Nanotargeted 188Re-(DXR)-Liposome for Internal Radiotherapy. Cancer Biotherapy & Radiopharmaceuticals, 2008. 23(6): p. 749-758. 50.Wang, S.J., et al., Knapp FF Jr, Nucl Med, 1998. 39(10): p. 1752–1757 51.Carlsson, G., et al., Estimation of liver tumor volume using different formulas—An experimental study in rats, Journal of Cancer Research and Clinical Oncology, 1983. 105(1): p. 20-23. 52.Fang, F., et al., Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Pharmacol Sin, 2005. 26(11): p. 1373-1381. 53.Cao, W., et al., Heated lipiodol as an embolization agent for transhepatic arterial embolization in VX2 rabbit liver cancer model. European Journal of Radiology, 2010. 73(2): p. 412-419. 54.Zhang, H., et al., Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother. Radiopharm, 2003. 18: p. 719–726. 55.Wohlfrom, M., et al., Endovascular irradiation with the liquid beta-emitter Rhenium-188 to reduce restenosis after experimental wall injury. Cardiovasc. Res, 2001. 49: p. 169–176. 56.Dadachova, E., et al., Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc. Natl. Acad, 2003. 100: p. 10942–10947. 57.Dadachova, E., et al., Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl. Med. Biol., 2002. 29: p. 13–18. 58.Scheffler, J., et al., Application of rhenium-188 HEDP in bone metastases therapy. Nucl. Med. Rev. Cent. East. Eur., 2003. 6: p. 55–57. 59.Chung, H. J., et al., Synthesis and characterization of Pluronic® grafted chitosan copolymer as a novel injectable biomaterial. Current Applied Physics, 2005. 5: p. 485–488. 60.Ganji, F., et al., Gelation time and degradation rate of chitosan-based injectable hydrogel. Journal of Sol–Gel Science and Technology, 2007. 42: p. 47–53. 61.Tan, M. L., et al., Review: doxorubicin delivery systems based on chitosan for cancer therapy. JPP., 2009. 61: p. 131-142. 62.Lee, H.S., et al., Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity, Cancer Res. Treat, 2008. 40(3): p.121–126. 63.Licata, S., et al., Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction, Chem. Res. Toxicol, 2000. 13(5): p. 414–420. 64.Wong, C.-Y.O., et al., Regional Yttrium-90 Microsphere Treatment of Surgically Unresectable and Chemotherapy-Refractory Metastatic Liver Carcinoma. Cancer Biotherapy & Radiopharmaceuticals, 2006. 21(4): p. 305-313. 65.Tarik F. Massoud., et al. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes & Development, 2003. 17: p. 545–580. 66.Mi, F.-L., Chitosan-polyelectrolyte complexation for the preparation of gel beads and controlled release of anticancer drug. I. Effect of phosphorous polyelectrolyte complex and enzymatic hydrolysis of polymer, J. Appl. Polymer Sci, 1999. 74: p. 1868–1879. 67.Mi, F.-L., et al., Kinetic study of chitosantri polyphosphate complex reaction and acid-resistive properties of the chitosan-tripolyphosphate gel beads prepared by in-liquid curing method, J. Polymer Sci. B Polymer. Phys, 1999. 37: p. 1551–1564. 68.J. Cho, et al., Physical gelation of chitosan in the presence of b-glycerophosphate: the effect of temperature, Biomacromolecules , 2005. 6: p. 3267–3275.
|